Daily Sepsis Research Analysis
Three studies advance sepsis science across bench-to-bedside domains: a preclinical study shows angelicin mitigates sepsis-associated encephalopathy via IKK2/NF-κB inhibition; a multi-omics analysis nominates VDAC2 as a protective node in cholesterol dysregulation and stratifies sepsis into prognostically relevant subtypes; and a burn-unit quality improvement program achieved zero CLABSI after phased implementation of routine line changes.
Summary
Three studies advance sepsis science across bench-to-bedside domains: a preclinical study shows angelicin mitigates sepsis-associated encephalopathy via IKK2/NF-κB inhibition; a multi-omics analysis nominates VDAC2 as a protective node in cholesterol dysregulation and stratifies sepsis into prognostically relevant subtypes; and a burn-unit quality improvement program achieved zero CLABSI after phased implementation of routine line changes.
Research Themes
- Targeted neuroinflammation modulation in sepsis-associated encephalopathy
- Systems biology of cholesterol metabolism and sepsis subtyping
- Infection prevention and device management in burn critical care
Selected Articles
1. Angelicin alleviates sepsis-associated encephalopathy via inhibition of IKK2 and the NF-κB pathway.
In CLP-induced SAE mice, angelicin improved neurobehavior, reduced BBB leakage, and shifted cytokines toward anti-inflammatory profiles. Mechanistically, multi-modal assays (transcriptomics, docking, SPR) support direct IKK2 inhibition and downstream NF-κB suppression.
Impact: This work identifies a druggable node (IKK2) and a phytochemical (angelicin) with robust preclinical efficacy across structural, molecular, and behavioral readouts in SAE.
Clinical Implications: While preclinical, the data support IKK2/NF-κB as a target for sepsis-associated encephalopathy and justify early-phase trials and biomarker-driven strategies to modulate neuroinflammation.
Key Findings
- Angelicin improved hippocampal structure and neurobehavior (novel object recognition, spontaneous alternation, water maze performance) after CLP.
- BBB integrity was preserved with reduced Evans blue leakage, decreased S100β/NSE, and increased tight junction proteins.
- Proinflammatory cytokines (Il-1β, Il-6, Tnf-α) decreased and Il-10 increased; transcriptomics implicated NF-κB pathway modulation.
- Docking and SPR showed direct inhibition of IKK2 by angelicin, linking mechanism to phenotypic rescue.
Methodological Strengths
- Randomized multi-dose design with comprehensive structural, molecular, and behavioral endpoints
- Convergent mechanistic validation (transcriptomics, molecular docking, SPR, inhibitor interventions)
Limitations
- Preclinical mouse model without human validation or pharmacokinetic/safety data
- Generalizability to heterogeneous human SAE and optimal dosing/timing remain unknown
Future Directions: Define PK/PD and brain penetration, assess IKK2 selectivity versus off-targets, and initiate biomarker-informed Phase I/II trials in sepsis-associated encephalopathy.
BACKGROUND: Sepsis-associated encephalopathy (SAE) is a critical neurological complication in patients with sepsis and is pathologically characterized by neuroinflammation, blood-brain barrier (BBB) damage and neurobehavioral dysfunction but remains therapeutically challenging because of the lack of targeted treatment options. PURPOSE: The objective of this study was to explore the protective effects of angelicin (ANG) against cecal ligation and puncture (CLP)-induced SAE in mice, particularly its ability to mitigate neuroinflammation, BBB damage, and neurobehavioural dysfunction, and to investigate the underlying mechanisms involved. STUDY DESIGN AND METHODS: A total of 168 mice were randomly divided into 7 groups: a sham-operated group (sham), a sham-treated group (sham + 10 mg/kg ANG), a CLP group, an angelicin low-dose group (CLP + 2.5 mg/kg ANG), an angelicin medium-dose group (CLP + 5 mg/kg ANG), an angelicin high-dose group (CLP + 10 mg/kg ANG) and a positive control group (CLP + DEX). A variety of experimental methods, including HE staining, Nissl staining, Evans blue staining, quantitative real-time PCR, western blotting, and behavioral trials, were used to evaluate the biological processes of neuroinflammation, the BBB, and neurobehavioral dysfunction in SAE. RESULTS: ANG alleviated pathological changes in CLP-induced SAE (as indicated by preserved hippocampal structural integrity and elevated Nissl body density), neurobehavioral dysfunction (as indicated by significantly increased exploration time for new objects, recognition index, spontaneous alternation rate, and time spent exploring the target quadrant of the water maze), BBB damage (as indicated by reduced fluorescence intensity of Evans blue leakage, decreased levels of S100β and NSE secretion, increased levels of tight junction protein transcripts, and protein expression), and the inflammatory response (as indicated by reduced levels of the proinflammatory factors Il-1β, Il-6, and Tnf-α, and increased levels of the anti-inflammatory factor Il-10). Transcriptome analysis revealed that the NF-κB signaling pathway was significantly altered following ANG treatment. Further molecular docking, SPR, cell transfection, and inhibitor intervention experiments demonstrated that ANG ameliorated neuroinflammation in SAE by inhibiting IKK2. CONCLUSION: ANG mitigated neuroinflammation, BBB damage, and neurobehavioral dysfunction in CLP-induced SAE mice by specifically inhibiting IKK2 activity and suppressing NF-κB signaling pathway activation, suggesting that ANG is a promising therapeutic candidate for SAE treatment.
2. Multi-omics nominates VDAC2 as a candidate protective locus in sepsis-associated cholesterol dysregulation.
Integrative multi-omics and machine learning nominate VDAC2 (with VDAC1 and LDLRAP1) as key nodes in sepsis-related cholesterol dysregulation. Two molecular subtypes with immunosuppression/metabolic reprogramming were identified, and an ensemble model predicted 28-day mortality across cohorts.
Impact: The study links lipid metabolism to immune dysregulation in sepsis, proposes a protective locus (VDAC2), and offers prognostic stratification with external validation—shaping hypotheses for targeted interventions.
Clinical Implications: Molecular subtyping and cholesterol-pathway targets (e.g., VDAC2 axis) may inform risk stratification and personalized therapies, pending prospective validation and functional studies.
Key Findings
- VDAC1, VDAC2, and LDLRAP1 emerged as hub genes for cholesterol dysregulation in sepsis via WGCNA and cross-cohort analyses.
- Two CMG-based NMF clusters were identified; the immunosuppressed/metabolic-reprogrammed cluster had poorer prognosis.
- An ensemble of 101 machine learning algorithms predicted 28-day mortality with high accuracy across cohorts.
- SMR and PheWAS supported causal/phenotypic associations of target genes; single-cell analysis mapped expression across immune subsets.
Methodological Strengths
- Integration of bulk and single-cell transcriptomics with cross-cohort validation
- Use of SMR/PheWAS for causal inference and ensemble machine learning for robust prognostication
Limitations
- Retrospective bioinformatics with heterogeneous public datasets and potential batch/confounding effects
- Limited experimental validation; prospective clinical validation and functional assays are needed
Future Directions: Functional validation of VDAC2 in sepsis models, lipid-targeted interventions stratified by molecular subtype, and prospective validation of the prognostic model.
Sepsis, a life-threatening condition, involves dysregulated cholesterol metabolism critical for immune regulation and cellular processes. This study employed multi-omics and machine learning to explore cholesterol metabolism in sepsis, aiming to identify novel therapeutic targets. Transcriptome and single-cell RNA sequencing data for sepsis were retrieved from the Gene Expression Omnibus (GEO) database. The limma package and WGCNA co-expression network were used to screen genes, hybridized with cholesterol metabolism genes (CMGs) to identify hub genes. Machine learning algorithms screened pivotal genes to construct diagnostic model, validating performance via multi-cohort Receiver Operating Characteristic (ROC) curve. Non-negative matrix factorization (NMF) based molecular typing using CMGs, and integration of 101 machine learning algorithms built prognostic models. Single-cell analysis characterized expression patterns of pivotal genes and key subsets. Causal effects and phenotypic associations of target genes were evaluated using Summary data-based Mendelian Randomization (SMR) and PheWAS. Integrated transcriptomic analysis identified three key genes (VDAC1, VDAC2, and LDLRAP1) associated with dysregulated cholesterol metabolism in sepsis. Machine learning-based diagnostic models exhibited high predictive accuracy. NMF clustering revealed two molecular subtypes, with Cluster 1 characterized by immunosuppression and metabolic reprogramming, linked to poorer prognosis. A machine learning model integrating 101 algorithms predicted 28-day mortality. The single-cell transcriptome atlas identified CD14
3. Getting to zero central line associated bloodstream infections: A multidisciplinary quality improvement project in a burn population.
A phased, multidisciplinary QI program centered on education, daily line-necessity review, and protocoled line replacement reduced CLABSI from 3.5% to 1.3% and achieved zero CLABSI the following year in burn patients. Line-days were the only independent risk factor.
Impact: Demonstrates a pragmatic pathway to near-elimination of CLABSI in a high-risk population, challenging existing device management recommendations for burns.
Clinical Implications: Burn ICUs may consider protocolized line replacement and rigorous necessity reviews to reduce CLABSI, while awaiting multicenter prospective evaluation to refine recommendations.
Key Findings
- CLABSI rate decreased from 3.5% (control) to 1.3% in phase 3, with zero CLABSI in 2023 after program maturation.
- Only central line-days independently predicted CLABSI; each additional day increased risk by 6.7%.
- Phased, multidisciplinary interventions including education and protocolized line replacement were feasible and impactful in a burn unit.
Methodological Strengths
- Real-world, unit-wide implementation with phased design and clear process components
- Objective outcome tracking over multiple years including a post-intervention year
Limitations
- Single-center before–after design without randomization; susceptible to secular trends and confounding
- Total sample size and adherence/fidelity metrics not detailed in the abstract
Future Directions: Conduct multicenter, prospective studies to evaluate routine line changes versus standard care in burn populations, incorporating cost-effectiveness and fidelity metrics.
BACKGROUND: Thermally injured patients are at higher risk for central-line-associated bloodstream infections (CLABSIs) than other critically ill patients. Despite this, the expectation is zero CLABSI for the burn population. Scarce literature exists regarding CLABSI prevention in burn-injured patients, with literature indicating divergent recommendations for the thermally injured compared to other critically ill cohorts. We undertook a quality improvement project (QI) to decrease our CLABSI rates. METHODS: All burn patients 15 years and older who were admitted to our burn unit from 2017 to 2022 with a central line placed during their stay were included. The burn team instituted a multidisciplinary CLABSI intervention in three phases that focused on education, line necessity discussions, and protocoled replacement of central lines. Chi-square, Fisher exact and Mann-Whitney tests were used to compare variables between those with and without CLABSIs. RESULTS: Eight patients developed nine CLABSIs. The study phases were similar with respect to clinically assessed variables. Patients with CLABSIs had larger burns, more central lines, more ventilator days, and longer lengths of stay. The CLABSI rate was 3.5% during the control period. After initially increasing, the rate decreased to 1.3% in phase 3 with no CLABSIs in the subsequent year (2023). Only line days were independently related to CLABSI, with an increase of 6.7% for each day the central line was in place. CONCLUSIONS: This multidisciplinary project was associated with a decrease in the CLABSI rates in burn patients reaching zero CLABSIs the following year. As this practice is counter to national central line management recommendations, it is imperative that multicenter prospective studies systematically evaluate the practice of routine line changes as part of CLABSI prevention in burn patients.